• Clinical data 90%
  • Efficacy 80%
  • Security 60%
  • Toxicity 40%

Hypericum perforatum
Herba Hyperici


Hypericum officinarum Crantz, Hypericum officinale Gater ex. Steud., Hypericum vulgare Lam. Clusiaceae is also referred to as Guttiferae or Hypericaceae.

General appearance

Stem glabrous greenish-yellow to brownish-yellow branching, 2-winged, cylindrical with 2 equidistant longitudinal bands. Leaves glabrous, generally sessile, opposite, greenish-grey, oval, 8–35mm long, with entire margins; laminal margin often more or less revolute-marginated. Brown-black glandular dots sometimes present along the edges; numerous pellucid glands on the entire surface. Flowers, 2 cm in diameter, regular, forming a broadly paniculate, compound cymose inflorescence at top of stem, composed of: 5 green, lanceolate sepals, containing punctiform, black glandular dots on the edges; 5 goldenyellow petals, with numerous glandular dots along margins; and 3 staminal blades, each divided into multiple golden-yellow stamens. Anthers with single, terminal, dark pigment dot. Ovary elongated and conical, parietal placentation, carries 3 styles. Fruits trilocular capsules containing numerous brown, triangular seeds.

Major chemical constituents

The major characteristic constituents include 0.05–0.30% naphthodianthrones (hypericin, pseudohypericin, hyperforin, adhyperforin); 2–4% flavonoids (hyperoside, quercitrin, isoquercitrin, rutin); and 7–15% catechin tannins.

Medicinal uses

Uses supported by clinical data
Hypericum perforatum: Symptomatic treatment of mild and moderate depressive episodes (classified as F32.0 and F32.1, respectively, in the International statistical classification of diseases and related health problems, Tenth revision (ICD-10).
Uses reported in pharmacopoeias and in traditional systems of medicine
Externally for the treatment of minor cuts, burns and skin ulcers. Topically for viral infections.
Uses described in folk medicine, not supported by experimental or clinical data
As an antiphlogistic agent in the treatment of inflammation of the bronchi and urogenital tract; treatment of biliary disorders, bladder irritation, the common cold, diabetes mellitus, dyspepsia, haemorrhoids, neuralgia, migraine headaches, sciatica and ulcers. Also used as a diuretic, an emmenagogue and an antimalarial agent.


Experimental pharmacology

Antidepressant activity

Behavioural studies, performed primarily in rodents, have demonstrated the antidepressant activity of Herba Hyperici by measuring the exploratory and locomotor activities of animals in an unknown environment. Intragastric administration of a 95% ethanol extract of the herb to male gerbils (2mg/kg body weight) suppressed clonidine-induced depression. Intragastric administration of the extract to male mice (5mg/kg body weight) enhanced exploratory activity in a foreign environment and significantly prolonged narcotic-induced sleeping time in a dose-dependent manner; the treated mice also exhibited reserpine antagonism. Similar to standard antidepressant drugs, the extract (6mg/kg body weight) increased the activity of mice in the waterwheel test following a single dose; prolonged administration (6mg/kg body weight, daily for 3 weeks) decreased aggressiveness in socially isolated male mice. Intraperitoneal administration of a 50% ethanol extract of the herb to mice (250mg/kg body weight) reduced the tail flick response to radiant heat, and significantly decreased swimming time in the forced swimming test (P < 0.05) and walking time on a rotating rod (P < 0.005), as well as exploratory activity (P < 0.05). Significant, dose-dependent, antidepressant activities were observed in the behavioural despair test and the learned helplessness paradigm in rats treated intragastrically with a carbon dioxide extract of the crude drug containing 38.8% hyperforin (30mg/kg body weight) or an ethanol extract containing 4.5% hyperforin (300mg/kg body weight) (P < 0.001). The results were comparable to those obtained following intraperitoneal administration of imipramine (10mg/kg body weight). Intragastric administration of an ethanol extract containing 4.5% hyperforin (50, 150 and 300mg/kg body weight, daily for 3 days) or a carbon dioxide extract devoid of hypericin but containing 38.8% hyperforin (5, 15 and 30mg/kg body weight, daily for 3 days) had similar antidepressant activity in rodents (rats and mice). In the same dosage range, the ethanol extract potentiated dopaminergic behavioural responses, whereas these effects were either absent or less pronounced in rodents treated with the carbon dioxide extract. In contrast, serotoninergic effects of the carbon dioxide extract were more pronounced than those of the ethanol extract. Intragastric administration of a methanol extract containing both hypericin and pseudohypericin (500mg/kg body weight) to mice produced a dose-dependent increase in ketamine induced sleeping time and also increased body temperature. The extract also decreased immobility time in the tail suspension test and forced swimming tests, which are both regarded as indicative of antidepressant activity. Intragastric administration of a 50% ethanol extract of the herb prolonged pentobarbital-induced sleeping time (13.25mg/kg body weight) and depressed the central nervous system in male mice (25.50mg/kg body weight). The observed effects were similar to those seen in mice treated with diazepam (2mg/kg body weight). Measurement of some metabolites of biological amines in the urine of various animal models has established a correlation between the excretion in the urine of 3-methoxy- 4-hydroxyphenylglycol, the main metabolite of noradrenaline, with the start of the therapeutic antidepressant activity. A hydroalcoholic extract of the herb inhibited serotonin (5-hydroxytryptamine, 5-HT) receptor expression in mouse brain synaptosome preparations in vitro (50mmol/l), and similar effects were observed during ex vivo experiments. In other studies, hydroalcoholic extracts of the herb inhibited serotonin reuptake (IC50 6.2–25.0mg/ml), and inhibited both gaminobutyric acid (GABA) reuptake (IC50 1mg/ml) and GABA type A receptor binding (IC50 3mg/ml) in vitro. A hydroalcoholic extract of the fresh flowers and buds of H. perforatum (containing 0.1% hypericin) was subjected to a series of assays involving 39 receptor types and two enzymes. Receptor assays exhibiting at least 50% radioligand displacement or 50% inhibition of monamine oxidase (MAO) were considered to be active. The extract demonstrated specific affinity for the GABA (types A and B), serotonin, benzodiazepine and inositol triphosphate receptors, nonspecific affinity for adenosine receptors and inhibited MAO types A and B. Purified hypericin lacked any significant MAO (type A or B) inhibitory activity at concentrations up to 10mmol/l, and had affinity only for N-methyl-D-aspartate (NMDA) receptors in rat forebrain membranes. An ethanol extract of the herb inhibited radioligand binding to the NMDA, GABA type A and GABA type B receptors (IC50 7.025, 3.240 and 3.310mg/ml, respectively). The extract also inhibited synaptosomal GABA and L-glutamate uptake in vitro (IC50 1.11 and 21.25mg/ml, respectively). A methanol or carbon dioxide extract of the herb, and pure hyperforin significantly inhibited synaptosomal uptake of serotonin, noradrenaline, dopamine, L-glutamate and GABA in vitro. The carbon dioxide extract (containing 38.8% hyperforin) was more active than the methanol extract (containing 4.5% hyperforin), due to the higher hyperforin concentration. Inhibition was most pronounced with purified hyperforin, showing the following order of affinity: noradrenaline ≥ dopamine > GABA ≥ serotonin >> glutamate (IC500.043–0.445mg/ml). Neither hyperforin nor the carbon dioxide extract inhibited the activity of MAO type A or B at concentrations up to 50mg/ml. A methanol extract of dried H. perforatum flowers inhibited radiolabelledflumazenil binding to the benzodiazepine sites of the GABA receptor in rat brain Herba Hyperici 155 preparations in vitro (IC50 6.83mg/ml). The number of serotonergic 5HT1 A and 5-HT2 A receptors significantly increased in the brains of rats treated with an ethanol extract of the herb (2.7 g/kg body weight) daily for 26 weeks, whereas the affinity of both serotonergic receptors remained unaltered. These data suggest that prolonged administration of the extract induced upregulation of the 5-HT1 A and 5-HT2 A receptors. The affinity of hypericin for 30 types of receptor and reuptake sites was determined in vitro. At 1mmol/l, hypericin inhibited less than 40% specific radioligand binding at all sites tested, except binding at the acetylcholine and sigma receptors. The mechanism of the antidepressant effect of Herba Hyperici is not well understood. Early studies focused on the inhibition of MAO and catechol-Omethyltransferase (COMT), the two enzymes responsible for the catabolism of biological amines, such as serotonin. Initial investigations analysed the in vitro inhibition of MAO using a series of xanthones isolated from extracts of the herb. In later studies, hypericin was reported to inhibit MAO type A (IC50 6.8 ¥ 10-5 mol/l) and type B (IC50 4.2 ¥ 10-5 mol/l) in rat brain mitochondria in vitro. However, analysis of the hypericin fraction used in these experiments revealed that at least 20% of the extract was composed of other constituents, including some flavonoid derivatives. Xanthonecontaining fractions, free of hypericin and tannins, of a hydroalcoholic extract of H. perforatum showed significant inhibition in vitro of MAO type A (which is specific for serotonin). In other investigations, only the flavone aglycone, quercitrin, and the xanthone derivative, norethyriol, showed significant inhibition of MAO type A. Hypericin was excluded as the active constituent, and the flavonols and 1,3,6,7-tetrahydroxyxanthone were reported to be the active constituents of a crude extract of the herb. Molecular modelling studies of the constituents of the herb also indicated that the flavonoids may be the most likely candidates for inhibitors of MAO, as their structures are similar to those of known MAO type A inhibitors, toloxotone and brofaromine. The MAO-inhibiting activity of six fractions of a hydroalcoholic extract of the herb was determined in vitro and ex vivo. In vitro inhibition of MAO type A in rat brain homogenates could only be shown at a concentration of 1–10mmol/l of a crude extract or a flavonoid-rich fraction. In ex vivo studies using albino rats, neither the crude extract nor the xanthone-containing fractions inhibited MAO type A or MAO type B after intraperitoneal administration of 300mg/kg body weight of the extract or 1–10nmol/l of the fractions. In addition, purified hypericin did not inhibit MAO type A either in vitro or ex vivo. The in vitro effects of hypericin, an ethanol extract, and fractions of the extract were tested for inhibition of MAO and COMT obtained from pig liver. Inhibition of MAO was seen with hypericin (1mmol/l),1 ethanol extract (0.1mmol/l),1 and a fraction containing hypericins and flavonols (0.01mmol/l). 1 Molar concentrations were based on a mean molar mass of 500. Weak inhibition of COMT was observed with hypericin and the ethanol extract (both at a concentration of 1mmol/l),1 whereas two fractions, containing flavonols and xanthones, inhibited COMT to a greater extent at 0.1mmol/l1. However, the inhibitory concentrations observed during this study appear to be too high to be of any clinical significance. Other possible mechanisms of the antidepressant effect of Herba Hyperici include its ability to modulate the production of mediators of inflammation such as cytokines, particularly interleukins. Strong suppression of interleukin-6 (IL-6) release was observed in blood samples from depressed patients treated with H. perforatum extract. IL-6 is involved in the modulation of the hypothalamic–pituitary–adrenal (HPA) axis within the nervous/immune system. Elevated IL-6 levels activate the HPA axis, thus increasing levels of adrenal hormones that play a role in depression.

Effect on smooth muscle contraction

A 95% ethanol extract or tincture of the herb (200mg/ml) inhibited bariumand histamine-induced smooth muscle contractions of guinea-pig ileum in vitro, and contractions of cat and mouse intestine. An ethyl acetate extract of the herb (0.1mg/ml) inhibited potassium chloride- and histamine-induced contractions in pig coronary artery in vitro.

Antibacterial and antiviral activity

A methanol extract of Herba Hyperici inhibited the growth in vitro of Escherichia coli, Proteus vulgaris, Streptococcus mutans, Streptococcus sanguis, Staphylococcus oxford and Staphylococcus aureus (MIC 0.31 1.25mg/ml). An acetone, hot aqueous or ethyl acetate extract of the herb was active against influenza virus A2 (Mannheim 57), herpes simplex virus 2, poliovirus II and vaccinia virus in vitro. However, a decoction or hydroalcoholic extract of H. perforatum dried stem was not active against herpes simplex virus 1 or 2, or HIV in vitro (100mg/ml). In vitro activity of hypericin has been demonstrated against Friend murine leukaemia virus, hepatitis B virus, murine cytomegalovirus, human cytomegalovirus (Davis strain), parainfluenza 3 virus, Sindbis virus, vaccinia virus, vesicular stomatitis virus and equine infectious anaemia virus. Hypericin and pseudohypericin also inhibited herpes simplex virus types 1 and 2, and HIV-1 in vitro. Hypericin inhibited the activity of HIV reverse transcriptase in vitro (IC50 0.77mmol/l), and inhibited herpes simplex virus, Rauscher murine leukaemia and Friend murine leukaemia viruses in mice after intravenous, intraperitoneal or intragastric administration. Intraperitoneal administration of a 5% aqueous extract of the herb to mice resulted in viricidal activity against tick-borne encephalitis virus. Hypericin displayed marginal activity in vitro against Molony murine leukaemia virus and did not show selective activity against herpes simplex 1 Molar concentrations were based on a mean molar mass of 500. virus, influenza virus A, adenovirus or poliovirus. However, incubation of the virus with hypericin prior to infection resulted in viricidal activity against all enveloped viruses tested (IC50 1.56–25mg/ml), but not against non enveloped viruses. The antiviral activity of hypericin appears to involve a photoactivation process that forms a singlet oxygen and inactivates both viral fusion and syncytia formation. Protein kinase C inhibition Numerous in vitro studies have demonstrated that hypericin is a potent inhibitor of protein kinase C. Hypericin treatment of glioma cell lines inhibited growth and also induced cell death due to protein kinase C.
Receptor tyrosine kinase activity of epidermal growth factor is also inhibited by hypericin and may be linked to its antiviral and antineoplastic effects. The inhibition of protein kinase C may contribute to the antiinflammatory effects of Herba Hyperici, as hypericin also inhibited the release of arachidonic acid and leukotriene B4.

Wound healing

External application of a 20% aqueous extract of the crude drug to the skin of guinea-pigs and rabbits accelerated healing of experimentally induced wounds. Intragastric administration of a 60% ethanol extract of the dried leaves to rats (0.1 ml/animal) accelerated healing of experimentally induced wounds by enhancing the strength and rate of wound contraction and epithelialization.

Clinical pharmacology

Antidepressant activity

Clinical trials without controls

The safety and efficacy of oral administration of Herba Hyperici has been assessed in more than 5000 patients in numerous case reports and studies. In a drug-monitoring study involving 3250 patients, 49% were assessed as being mildly depressed, 46% as moderately depressed and 3% as severely depressed at the beginning of the trial. The patients were treated with 300mg of a dried 80% methanol extract of the herb three times daily, and evaluated after 2 and 4 weeks of therapy. After treatment, 80% of patients had improved or were symptom-free, while 13–16% remained unchanged or were worse. Minor adverse reactions were reported in 2.4% of patients. A postmarketing trial was performed with 2404 patients with symptoms of mild to moderate depression who were treated with 2–4 capsules of an ethanol extract of the herb (equivalent to 0.6–1.8mg total hypericin) daily for 4–6 weeks. Symptomatic improvement was evaluated as good to very good in 77% of patients and satisfactory in 15%.
The effects of an ethanol extract of the herb on the electroencephalogram (EEG) of 40 patients with depression were determined following administration of the extract (equivalent to 0.5 mg total hypericin or 1.4 g crude drug) daily for 4 weeks. An increase in theta-activity, a decrease in alpha-activity and no change in beta-activity were observed, indicating the induction of relaxation. A significant increase in nocturnal melatonin plasma concentration was observed in 13 healthy subjects treated with a hydroethanolic extract of the herb (equivalent to 0.53 mg total hypericin) daily for 3 weeks. A significant increase in the concentration of neurotransmitters in the urine was observed 2 hours after administration of a standardized ethanol extract of the crude drug to six women with symptoms of depression.

Reviews of clinical trials

The results from over 28 controlled clinical trials involving oral administration of Herba Hyperici have been published. Twelve of the trials, involving 950 patients, were conducted using an ethanol extract of the herb, while the other 16 trials of 1170 patients used a dried 80% methanol extract. A systematic review and meta-analysis of 23 of the randomized clinical trials involving 1757 patients assessed the efficacy of the herb in the symptomatic treatment of mild to moderate depression. Twenty trials were double-blind, one was single-blind and two were open studies. Fifteen of the trials involving 1008 patients were placebo-controlled and eight studies of 749 patients were comparison trials with other antidepressant drugs. With the exception of two trials, all studies had treatment periods of 4–8 weeks. The daily dosage ranged from 0.4 to 2.7mg hypericin in 300–1000mg of a standardized extract of the herb. Seventeen trials used the Hamilton Rating Scale for Depression (Hamilton Depression Rating Scale), which focuses primarily on somatic symptoms, to measure effectiveness, while 12 trials used the Clinical Global Impression Scale. The latter involves observer-rated analysis of severity of illness, global improvement and efficacy. The meta analysis concluded that the herb was significantly superior to the placebo and was as effective as standard antidepressants such as maprotiline or imipramine (75 mg three times daily). Fewer side-effects were seen in the herb-treated patients (19.8%) than in those receiving standard antidepressants (52.8%). A systematic, criteria based review of 18 controlled clinical trials using either ethanol or methanol extracts of the herb as a treatment for depression was carried out. Twelve of the trials (nine placebo-controlled and three comparison trials) met the methodological inclusion criteria and were included in the review. The results of the cumulative data show that extracts of the herb were superior to the placebo for the symptomatic treatment of depression as measured by the Hamilton Depression Rating Scale. Results of the comparison studies with maprotiline (75mg daily) and imipramine (50–75mg daily) and other standard antidepressants suggest that extracts of the herb have a similar therapeutic profile. Some flaws in the reported studies included no intention to treat analysis, lack of control over compliance, and insufficient description of the extract or placebo used.
A review of 12 double-blind, placebo-controlled and three comparison clinical trials assessed the efficacy of the herb for the treatment of mild to moderate depression, and the methodology used to perform the studies. The review concluded that the antidepressant activity of a standardized extract of the herb (300mg standardized to contain 0.9mg hypericin three times daily for 4–8 weeks) was sufficiently documented. However, it also concluded that no dosefinding studies had been conducted, and that studies on inpatients with severe depression and endogenously depressed patients were lacking. In the three comparison studies, the daily dose of 75mg maprotiline or 30mg amitriptyline was viewed as too low. The review concluded that further trials of longer duration in comparison with higher doses of standard antidepressants are warranted. A double-blind, randomized, multicentre study was performed to evaluate the efficacy, safety and tolerability of a daily dose of 900mg hydroalcoholic extract of the herb or 75 mg amitriptyline. After a 1-week placebo run-in phase, 156 patients were treated with 300mg extract or 25mg amitriptyline, three times daily for 6 weeks. The patients were assessed before and after treatment. The Hamilton Depression Rating Scale changed from 20 to 10 in the extracttreated patients and from 21 to 6 in the amitriptyline-treated patients (P < 0.05). The Montgomery-Asberg Rating Scale for Depression changed from 27 to 13 in the extract-treated patients, and from 26 to 6.5 in the amitriptyline-treated patients (P < 0.05). Similar scores in the Clinical Global Impression Scale were observed in both groups. In a randomized, double-blind, multicentre trial the effectiveness of a standardized dried 80% methanol extract of the herb (containing 0.3% hypericin) was compared with that of imipramine in 209 patients with recurrent depressive disorder, current episode severe without psychotic symptoms. Patients were treated daily with 1800mg extract or 150mg imipramine for 6 weeks. Assessment of patients before and after treatment revealed the following changes. In the Hamilton Depression Rating Scale: from 25.3 to 14.4 in the extract-treated patients, and from 26.1 to 13.4 in the imipramine treated patients (P < 0.021). In the von Zerssen Depression Scale: from 28.9 to 13.6 in the extract-treated patients, and from 26 to 6.5 in the imipramine-treated patients (P < 0.05). Results in the Clinical Global Impression Scale showed a trend in favour of imipramine. Although the efficacy of the extract was not significantly different from that of imipramine, analysis of the patient subgroups showed that it was most effective in patients with moderately severe depression. A prospective, randomized, double-blind, placebo-controlled, multicentre study assessed the safety and efficacy of a standardized ethanol extract of the herb for the treatment of 151 patients with mild and moderate depressive episodes (classified as F32.0 and F32.1, respectively, in 1CD-10). Patients received either one 250 mg tablet of the extract (equivalent to 1mg hypericin) or a placebo twice daily for 6 weeks. The primary efficacy variable was the Hamilton Depression Rating Scale, and secondary variables were the risk–benefit Clinical Global Impression Scales I–III and Visual Analogue Scale (a validated, patient self assessment test). Decreases were seen in the Hamilton Depression Rating Scale in 56% of patients treated with the extract, whereas decreases were seen in only 15% of patients who received the placebo (24). A randomized, double blind, placebo-controlled, multicentre study assessed the clinical efficacy and safety of two extracts of the herb differing in their hyperforin content (0.5% or 5.0% hyperforin) in 147 patients suffering from mild to moderate depression as classified in the Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV) of the American Psychiatric Association. The patients received either 900 mg of one of the extracts or a placebo daily for 42 days. The patients who received the extract containing 5% hyperforin showed the largest decrease in the Hamilton Depression Rating Scale (a reduction of 10.3; P = 0.004, compared to the placebo). A reduction of 8.5 following treatment with the extract containing 0.5% hyperforin and of 7.9 in the placebo-treated group was seen. In a double-blind, placebo-controlled, crossover study, 12 healthy volunteers treated with a dried hydromethanolic extract of the herb (300mg three times daily for 4 weeks) showed improved sleep quality with an increase in deepslee phases. A randomized, double-blind, placebo controlled study of 54 healthy volunteers evaluated the central pharmacodynamic effects of two extracts of the herb with different hyperforin contents (0.5% or 5.0%) but identical hypericin content. Healthy volunteers received either 900mg (300mg three times daily) of one of the extracts or a placebo daily for 8 days. A quantitative topographic electroencephalogram (qEEG) was performed on days 1 and 8 as an indicator of drug-induced pharmacological activity. In both treatment groups, reproducible central pharmacodynamic effects were observed between 4 and 8 hours after administration, and were confirmed on day 8. The extract containing 5% hyperforin showed a marked tendency to produce greater increases in qEEG baseline power performances than the extract containing 0.5% hyperforin. Higher baseline outputs were observed on day 8 in the delta-, theta- and alpha-1 frequencies. Patients treated with the extract containing 5% hyperforin had an increase in qEEG power performance in the deltafrequency after a single dose and in the theta- and alpha-1 frequencies after 8 days of treatment, when compared with placebo treatment. In a double-blind, placebo-controlled, crossover study, 12 healthy volunteers were treated with 900mg (300mg three times daily) of a dried hydromethanolic extract of the herb for 6 weeks, and the effects on the EEG were assessed. A reduction in alpha-activity and audiovisual latencies in evoked potentials and an increase in beta- and theta-activities were demonstrated (104). Another randomized, double-blind, clinical trial of 24 healthy volunteers compared the effects of a dried hydromethanolic extract of the herb with those of maprotiline on the resting EEG and audio-visual latencies in evoked potentials. After 4 weeks of treatment, an increase in theta- and beta-2 activity was observed in patients treated with 900mg of a standardized hydroalcoholic extract (300mg three times daily), while a decrease in thetaactivity was seen in patients treated with 30mg maprotiline (10mg three times
daily). The extract also induced an increase of deep sleep as demonstrated by visual analysis of the sleeping phases and automatic analysis of slow-wave EEG activities. Rapid eye movement sleep was not influenced. A randomized, single-blind study evaluated the efficacy of the herb for the treatment of seasonal affective disorders (SAD) in conjunction with light therapy. Twenty patients with SAD were treated with 900mg (300mg three times daily) of a hydroalcoholic extract of the herb daily for 4 weeks, combined with either bright (3000 lux) or dim light (<300lux) conditions. Light therapy was carried out for 2 hours daily. A significant reduction of the Hamilton Depression Rating Scale in both groups, but no statistically significant difference between the two groups, was observed.

Photodynamic effects

The photodynamic effects of hypericin, incorporated into a non-ionic hydrophilic ointment base, were assessed after external application to the skin of patients with herpes communis. The infected dermal surface of treated patients recovered rapidly and the effects lasted in most cases.


Single-dose pharmacokinetics of hypericin and pseudohypericin were determined in 12 healthy male volunteers. After a single dose of 300, 900 or 1800mg extract (equivalent to 250, 750 or 1500mg hypericin, respectively, and 526, 1578 or 3156mg pseudohypericin, respectively), plasma levels of the hypericins were measured by high performance liquid chromatography for up to 3 days. The median plasma levels were 1.5, 4.1 and 14.2 ng/ml for hypericin, and 2.7, 11.7 and 30.6 ng/ml for pseudohypericin, for the three stated doses, respectively. The median half-life of hypericin was 24.8–26.5 hours and 16.3–36.0 hours for pseudohypericin. The median lag-time of absorption was 2.0–2.6 hours for hypericin and 0.3–1.1 hours for pseudohypericin. During long-term dosing (900mg daily), a steady state was reached after 4 days. The mean maximum plasma level during the steady state was 8.5ng/ml for hypericin and 5.8ng/ml for pseudohypericin. A randomized, placebo-controlled clinical trial was performed to evaluate the pharmacokinetics and dermal photosensitivity of hypericin and pseudohypericin in 13 healthy volunteers after administration of a single dose of either a placebo or 900, 1800 or 3600 mg of the extract(equivalent to 0.00, 2.81, 5.62 and 11. 25mg total hypericin [combined hypericin and pseudohypericin], respectively). The maximum total hypericin plasma levels observed at 4 hours after administration were 0, 28, 61 and 159 ng/l, respectively. Before and 4 hours after drug intake, the subjects were exposed to increasing doses of solarsimulated irradiation on small areas of their backs. No dose-related increase in light sensitivity was observed. In the multiple-dose analysis, 50 healthy volunteers received 600mg extract of the herb three times during 1 day only. A slight increase in solar-simulated irradiation sensitivity was observed.
In a randomized, four-way crossover study without controls involving six healthy volunteers, the pharmacokinetics of hyperforin were determined after administration of single doses of 300, 600, 900 or 1200mg of an alcohol extract containing 5% hyperforin. The maximum plasma level of hyperforin (150ng/ml) was reached 3.5 hours after administration of 300mg of the extract. The hyperforin half-life and mean residence time were 9 and 12 hours, respectively. The pharmacokinetics were linear up to 600mg of the extract. Increasing the dose to 900 or 1200mg of extract resulted in values for maximum clearance and area under the curve lower than those expected from linear extrapolation of data from the lower doses. The pharmacokinetics of hyperforin were studied in nine healthy volunteers, as part of a double-blind, randomized, placebo-controlled study of 54 subjects. The subjects received either a single dose of 900 mg of an alcohol extract containing 5% hyperforin, or 300 mg of an alcohol extract containing 5% hyperforin three times daily for 8 days. No accumulation of hyperforin in the plasma was observed. On the basis of the area under the curve values from the multiple-dose study, the estimated steady-state plasma concentration of hyperforin was approximately 100ng/ml.


Herba Hyperici is contraindicated in cases of known allergy to plants of the Clusiaceae family.


As with other antidepressant drugs, observation of the therapeutic effects of Herba Hyperici may require 2–4 weeks of therapy. If a significant antidepressant effect is not observed after 6 weeks of treatment, a physician should be consulted.

News and Journals

1. European pharmacopoeia, 3rd ed., Suppl. 2000. Strasbourg, Council of Europe, 1999.
2. American herbal pharmacopeia and therapeutic compendium. Santa Cruz, CA, American
Herbal Pharmacopeia, 1997.
3. St John’s wort. In: The United States pharmacopeia 24: national formulary 19. Rockville,
MD, United States Pharmacopeial Convention, 2000:2509–2510.
4. Blaschek W et al., eds. Hägers Handbuch der pharmazeutischen Praxis. Folgeband 2:
Drogen A–K, 5th ed. Berlin, Springer-Verlag, 1998.
5. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois at
Chicago, IL, February 9, 1998 production (an online database available directly
through the University of Illinois at Chicago or through the Scientific and Technical
Network [STN] of Chemical Abstracts Services).
6. Pignatti S. Flora Italica. Torino, Unione Tipografico Editrice Torinese, 1982.
7. Bisset NG. Herbal drugs and phytopharmaceuticals. Boca Raton, FL, CRC Press, 1994.
8. Bombardelli E, Morazzoni P. Hypericum perforatum. Fitoterapia, 1995, 66:43–68.
9. British herbal pharmacopoeia. London, British Herbal Medicine Association, 1996.
10. Pharmacopoea helvetica, 8th ed. Berne, Département fédéral de l’intérieur, 1997.
11. Pharmacopée française. Paris, Adrapharm, 1996.
12. Piperopoulos G et al. Determination of naphthodianthrones in plant extracts from
Hypericum perforatum L. by liquid chromatography–electrospray mass spectrometry.
Journal of Chromatography B: Biomedical Applications, 1997, 695:309–316.
13. Quality control methods for medicinal plant materials. Geneva, World Health Organization,
14. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996.
15. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World
Health Organization, 1997 (document WHO/FSF/FOS/97.7).
16. Brolis M et al. Identification by high-performance liquid chromatography–diode
array detection–mass spectrometry and quantification by high-performance liquid
chromatography–UV absorbance detection of active constituents of Hypericum
perforatum. Journal of Chromatography A, 1998, 825:9–16.
17. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of
the herb of Hypericum perforatum L. Pharmacopsychiatry, 1997, 30:129–134.
18. International statistical classification of diseases and related health problems, Tenth revision
(ICD-10), Volume 1. Geneva, World Health Organization, 1992.
19. Ernst E. St John’s wort, an antidepressant? A systematic, criteria-based review.
Phytomedicine, 1995, 2:67–71.
20. Laakmann G et al. St John’s wort in mild to moderate depression: the relevance of
hyperforin for the clinical efficacy. Pharmacopsychiatry, 1998, 31 (Suppl. 1):S54–S59.
21. Linde K et al. St John’s wort for depression—an overview and meta-analysis of
randomized clinical trials. British Medical Journal, 1996, 313:253–258.
22. Maisenbacher HJ et al. Therapie von Depressionen in der Praxis. Ergebnisse einer
Anwendungsbeobachtung mit Hyperici herba. Natura Medica, 1992, 7:394–399.
23. Pieschl D et al. Zur Behandlung von Depressionen. Verblindstudie mit einem
pflanzlichen Extrakt Johanniskraut. Therapiewoche, 1989, 39:2567–2571.
24. Schrader E et al. Hypericum treatment of mild–moderate depression in a placebocontrolled
study. A prospective, double-blind, randomized, placebo-controlled,
multicentre study. Human Psychopharmacology, 1998, 13:163–169.
25. Schultz H, Jobert M. Effects of Hypericum extract on the sleep EEG in older volunteers.
Journal of Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S39–S43.
26. Schultz H et al. Clinical trials with phyto-psychopharmacological agents.
Phytomedicine, 1997, 4:379–387.
27. Volz HP. Controlled clinical trials of Hypericum extracts in depressed patients—an
overview. Pharmacopsychiatry, 1997, 30:72–76.
28. Vorbach EU, Arnoldt KH, Hübner W-D. Efficacy and tolerability of St John’s wort
extract LI 160 versus imipramine in patients with severe depressive episodes
according to ICD-10. Pharmacopsychiatry, 1997, 30:81–85.
29. Wheatley D. LI 160, an extract of St John’s wort, versus amitriptyline in mildly to
moderately depressed outpatients—a controlled 6-week clinical trial. Pharmacopsychiatry,
1997, 30:77–80.
30. Wheatley D. Hypericum extract: potential in the treatment of depression. CNS
Drugs, 1998, 9:431–440.
31. Woelk H et al. Benefits and risks of the Hypericum extract LI 160: drugmonitoring
study with 3250 patients. Journal of Geriatric Psychiatry and Neurology,
1994, 7 (Suppl. 1):S34–S38.
32. Blumenthal M et al., eds. The complete German Commission E monographs. Austin,
TX, American Botanical Council, 1998.
33. Ivan H. Preliminary investigations on the application of Hypericum perforatum in
herpes therapy. Gyogyszereszet, 1979, 23:217–218.
34. Öztürk Y. Testing the antidepressant effects of Hypericum species on animal models.
Pharmacopsychiatry, 1997, 30:125–128.
35. Okpanyi SN, Weischer ML. Tierexperimentelle Untersuchungen zur psychotropen
Wirksamkeit eines Hypericum-Extraktes. Arzneimittel-Forschung, 1987, 37:10– 13.
36. Öztürk Y et al. Effects of Hypericum perforatum L. and Hypericum calycinum L. extracts
on the central nervous system in mice. Phytomedicine, 1996, 3:139–146.
37. Chatterjee SS et al. Hyperforin as a possible antidepressant component of Hypericum
extracts. Life Sciences, 1998, 63:499–510.
38. Bhattacharya SK, Chakrabaarti A, Chatterjee SS. Activity profiles of two
hyperforin-containing Hypericum extracts in behavioral models. Pharmacopsychiatry,
1998, 31 (Suppl. 1):S22–S29.
39. Dimpfel W et al. Effects of a methanolic extract and a hyperforin-enriched CO2
extract of St John’s wort (Hypericum perforatum) on intracerebral field potentials in
the freely moving rat. Pharmacopsychiatry, 1998, 31 (Suppl. 1):S30–S35.
40. Butterweck V et al. Effects of the total extract and fractions of Hypericum perforatum
in animal assays for antidepressant activity. Pharmacopsychiatry, 1997, 30: 117–124.
41. Girzu M et al. Sedative activity in mice of a hydroalcohol extract of Hypericum
perforatum L. Phytotherapy Research, 1997, 11:395–397.
42. Mülder H, Zöller M. Antidepressive Wirkung eines auf den Wirkstoffkomplex
Hypericin standardisierten Hypericum-Extrakts. Biochemische und klinische Untersuchungen.
Arzneimittel-Forschung, 1984, 34:918–920.
43. Müller WE, Rossol R. Effects of Hypericum extract on the expression of serotonin
receptors. Journal of Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S63–S64.
44. Neary JT, Bu YR. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine
in astrocytes. Brain Research, 1999, 816:358–363.
45. Perovic S, Müller WEG. Pharmacological profile of Hypericum extract: effect
on serotonin uptake by postsynaptic receptors. Arzneimittel-Forschung, 1995, 45:1145–1148.
46. Müller WE et al. Effects of Hypericum extract LI 160 on neurotransmitter uptake
systems and adrenergic receptor density. Second International Congress on Phytomedicine,
Munich, 1996.
47. Cott J, Misra R. Medicinal plants: a potential source for new psychotherapeutic
drugs. In: Kanba S et al., eds. New drug development from herbal medicines in neuropsychopharmacology.
New York, Brunner/Mazel Inc., 1997.
48. Wonnemann M et al. Effects of Hypericum extract on glutamatergic and gabaminergic
receptor systems. Pharmazie, 1998, 53:38.
49. Chatterjee SS et al. Hyperforin inhibits synaptosomal uptake of neurotransmitters
in vitro and shows antidepressant activity in vivo. Pharmazie, 1998, 53 (Suppl. 1):9.
50. Müller WE et al. Hyperforin represents the neurotransmitter reuptake inhibiting
constituent of Hypericum extract. Pharmacopsychiatry, 1998, 31 (Suppl. 1):16–21.
51. Baureithel KH et al. Inhibition of benzodiazepine binding in vitro by amentoflavone,
a constituent of various species of Hypericum. Pharmaceutica Acta Helvetiae, 1997, 72:153–157.
52. Teufel-Mayer R, Gleitz J. Effects of long-term administration of Hypericum extracts
on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors.
Pharmacopsychiatry, 1997, 30:113–116.
53. Raffa RB. Screen of receptor and uptake-site activity of hypericin component of St
John’s wort reveals sigma receptor binding. Life Sciences, 1998, 62:PL265–PL270.
54. Suzuki O et al. Inhibition of monoamine oxidase by isogentisin and its 3-Oglucoside.
Biochemical Pharmacology, 1978, 27:2075–2078.
55. Suzuki O et al. Inhibition of type A and type B monoamine oxidase by naturally
occurring xanthones. Planta Medica, 1981, 42:17–21.
56. Suzuki O et al. Inhibition of monoamine oxidase by hypericin. Planta Medica, 1984,
57. Hölzl J et al. Investigation about antidepressive and mood-changing effects of
Hypericum perforatum. Planta Medica, 1989, 55:643.
58. Demisch L et al. Identification of selective MAO type A inhibitors in Hypericum
perforatum L. (Hyperforat®). Pharmacopsychiatry, 1989, 22:194.
59. Sparenberg B et al. Untersuchungen über antidepressive Wirkstoffe von Johanniskraut.
Pharmazie Zeitschrift Wissenschaften, 1993, 138:50.
60. Höltje HD, Walper A. Molecular modeling of the antidepressive mechanism of
Hypericum ingredients. Nervenheilkunde, 1993, 12:339–340.
61. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of Hypericum
extract. Journal of Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S57–S59.
62. Thiede HM, Walper A. Inhibition of MAO and COMT by Hypericum extracts and
hypericin. Journal of Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S54–S56.
63. Thiele B et al. Modulation of cytokine expression by Hypericum extract. Journal of
Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S60–S62.
64. Itokawa H et al. Studies on the constituents of crude drugs having inhibitory activity
against contraction of the ileum caused by histamine or barium chloride. I.
Screening test for the activity of commercially available crude drugs and the related
plant materials. Shoyakugaku Zasshi, 1983, 37:223–228.
65. Zaitseva IM. The effect of common St John’s wort on the gastrointestinal system.
Zdravookhr Beloruss, 1966, 12:23.
66. Melzer R et al. Vasoactive properties of procyanidins from Hypericum perforatum L.
in isolated porcine coronary arteries. Arzneimittel-Forschung, 1991, 41:481–483.
67. Barbagallo C, Chisari G. Antimicrobial activity of three Hypericum species. Fitoterapia,
1987, 58:175–177.
68. May G, Willuhn G. Antiviral activity of aqueous extracts from medicinal plants in
tissue cultures. Arzneimittel-Forschung, 1978, 28:1–7.
69. Mishenkova EL et al. Antiviral properties of St John’s wort and preparations
produced from it. Trudy S’ezda mikrobiologii Ukrainskoi, 1975, 4:222.
70. Pacheco P et al. Antiviral activity of Chilean medicinal plant extracts. Phytotherapy
Research, 1993, 7:415–418.
71. Anderson DO et al. In vitro virucidal activity of selected anthraquinones and
anthraquinone derivatives. Antiviral Research, 1991, 162:185–196.
72. Carpenter S, Kraus GA. Photosensitization is required for inactivation of equine
infectious anemia virus by hypericin. Photochemistry and Photobiology, 1991, 53:169–174.
73. Hudson JB et al. Antiviral assays on phytopharmaceuticals: the influence of reaction
parameters. Planta Medica, 1994, 604:329–332.
74. Lavie G et al. Hypericin as an antiretroviral agent. Mode of action and related
analogues. Annals of the New York Academy of Sciences, 1992:556–562.
75. Lopez-Bazzocchi I et al. Antiviral activity of the photoactive plant pigment hypericin.
Photochemistry and Photobiology, 1991, 54:95–98.
76. Moraleda G et al. Inhibition of duck hepatitis B virus replication by hypericin.
Antiviral Research, 1993, 20:223–247.
77. Wood S et al. Antiviral activity of naturally occurring anthraquinones and anthraquinone
derivatives. Planta Medica, 1990, 56:651–652.
78. Cohen PA et al. Antiviral activities of anthraquinones, bianthrones and hypericin
derivatives from lichens. Experientia, 1996, 523:180–183.
79. Degar S et al. Inactivation of the human immunodeficiency virus by hypericin: evidence
for photochemical alterations of p24 and a block in uncoating. AIDS Research
and Human Retroviruses, 1992, 8:1929–1936.
80. Lavie G et al. Studies of the mechanisms of action of the antiretroviral agents
hypericin and pseudohypericin. Proceedings of the National Academy of Sciences of the
United States of America, 1989, 86:5963–5967.
81. Meruelo D et al. Therapeutic agents with dramatic antiretroviral activity and
little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.
Proceedings of the National Academy of Sciences of the United States of America,1988, 85:5230–5234.
82. Tang J et al. Virucidal activity of hypericin against enveloped and non-enveloped
DNA and RNA viruses. Antiviral Research, 1990, 136:313–325.
83. Weber ND et al. The antiviral agent hypericin has in vitro activity against HSV-1
through non-specific association with viral and cellular membranes. Antiviral Chemistry
and Chemotherapy, 1994, 5:83–90.
84. Schinazi RF et al. Anthraquinones as a new class of antiviral agents against human
immunodeficiency virus. Antiviral Research, 1990, 135:265–272.
85. Fokina GI et al. Experimental phytotherapy of tick-borne encephalitis. Soviet Progress
in Virology, 1991, 1:27–31.
86. Lenard J et al. Photodynamic inactivation of infectivity of human immunodeficiency
virus and other enveloped viruses using hypericin and Rose bengal: inhibition
of fusion and syncytia formation. Proceedings of the National Academy of Sciences
of the United States of America, 1993, 901:158–162.
87. Agostinis P et al. Photosensitized inhibition of growth factor-regulated protein
kinases by hypericin. Biochemical Pharmacology, 1995, 4911:1615–1622.
88. Agostinis P et al. A comparative analysis of the photosensitized inhibition of
growth factor-regulated protein kinases by hypericin derivatives. Biochemical and
Biophysical Research Communications, 1996, 2203:613–617.
89. De Witte PA et al. Inhibition of epidermal growth factor receptor tyrosine kinase
activity by hypericin. Biochemical Pharmacology, 1993, 46:1929–1936.
90. Lavie G et al. The chemical and biological properties of hypericin A compound
with a broad spectrum of biological activities. Medical Research Reviews, 1995,
91. Samel D, De Witte P. Selective inhibition of PK-C activity by Fagopyrum esculentum
extract. Phytotherapy Research, 1996, 10 (Suppl. 1):S156–S158.
92. Zhang W et al. Enhancement of radiosensitivity in human malignant glioma cells
by hypericin in vitro. Clinical Cancer Research, 1996, 25:843–846.
93. Couldwell WT et al. Hypericin: a potential antiglioma therapy. Neurosurgery, 1994,
94. Panossian AG et al. Immunosuppressive effects of hypericin on stimulated human
leucocytes: inhibition of the arachidonic acid release, leukotriene B4 and
interleukin-1a production and activation of nitric oxide formation. Phytomedicine,
1996, 3:19–28.
95. Fedorchuk AM. Effect of Hypericum perforatum on experimentally infected wounds.
Mikrobiologichnii Zhurnal (Kiev), 1964, 26:32.
96. Lazareva KN et al. The results of a study of some drug plants of the Bashkir
USSR. Sbornik Nauchnykh Trudov Bashkir Gosudarstvennogo Meditsinskii Institut, 1968, 17:54.
97. Rao SG et al. Calendula and Hypericum: two homeopathic drugs promoting wound
healing in rats. Fitoterapia, 1991, 62:508–510.
98. Daniel K. Kurze Mitteilung über 12 jährige therapeutische Erfahrungen mit
Hypericin. Klinische Wochenschrift, 1951, 29:260–262.
99. Schakau D et al. Risk/benefit profile of St John’s wort extract. Psychopharmakotherapie,
1996, 3:116–122.
100. Kugler J et al. Therapie depressiver Zustände. Hypericum-Extrakt Steigerwald als
Alternative zur Benzodiazepin-Behandlung. Zeitschrift für Allgemeine Medizin, 1990, 66:21–29.
101. Demisch L et al. Einfluss einer subchronischen Gabe von Hyperforat auf die
nächtliche Melatonin- und Kortisolsekretion bei Probanden. Nünberg, Arbeitsgemeinschaft
für Neuropsychopharmakologie und Pharmakopsychiatrie Symposium Abstract 1991.
102. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC,
American Psychiatric Association, 1994.
103. Schellenberg R et al. Pharmacodynamic effects of two different Hypericum extracts
in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry, 1998, 31
(Suppl. 1):S44–S53.
104. Johnson D. Neurophysiologische Wirkungen von Hypericum im Doppelblindversuch
mit Probanden. Nervenheilkunde, 1991, 10:316–317.
105. Johnson D et al. Effects of Hypericum extract LI 160 compared with maprotiline on
resting EEG and evoked potentials in 24 volunteers. Journal of Geriatric Psychiatry
and Neurology, 1994, 7 (Suppl. 1):S44–S46.
106. Martinez B et al. Hypericum in the treatment of seasonal affective disorders. Journal
of Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S29–S33.
107. Kasper S. Treatment of seasonal affective disorder (SAD) with Hypericum extract.
Pharmacopsychiatry, 1997, 30 (Suppl. 1):S89–S93.
108. Staffeldt B et al. Pharmacokinetics of hypericin and pseudohypericin after oral
intake of the Hypericum perforatum extract LI 160 in healthy volunteers. Journal of
Geriatric Psychiatry and Neurology, 1994, 7 (Suppl. 1):S47–S53.
109. Brockmöller J et al. Hypericin and pseudohypericin: pharmacokinetics and effects
on photosensitivity in humans. Pharmacopsychiatry, 1997, 30:94–101.
110. Biber A et al. Oral bioavailability of hyperforin from Hypericum extracts in rats and
human volunteers. Pharmacopsychiatry, 1998, 31 (Suppl. 1):S36–S43.
111. Konig CD. Hypericum perforatum L. (gemeines Johanniskraut) als Therapeutikum bei
depressiven Verstimmungszuständen—eine Alternative zu synthetischen Arzneimitteln?
[Dissertation]. Basel, University of Basel, 1993.
112. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum
extract. Pharmacopsychiatry, 1997, 30 (Suppl. 1):S108–S112.
113. Nebel A et al. Potential metabolic interaction between St John’s wort and theophylline.
Annals of Pharmacotherapy, 1999, 33:502.
114. Johne A et al. Interaction of St John’s wort extract with digoxin. In: Jahreskongress
für klinische Pharmakologie. Berlin, 1999.
115. Ernst E. Second thoughts about safety of St John’s wort. Lancet, 1999, 354:2014–2016.
116. Lantz MS, Buchalter E, Giambanco V. St John’s wort and antidepressant drug interactions
in the elderly. Journal of Geriatric Psychiatry and Neurology, 1999, 12:7–10.
117. Piscitelli SC et al. Indinavir concentrations and St John’s wort. Lancet, 2000,355:547–548.
118. Okpanyi SN et al. Genotoxizität eines standardisierten Hypericum Extrakts.
Arzneimittel–Forschung, 1990, 40:851–855.
119. Poginsky B et al. Johanniskraut (Hypericum perforatum L.). Genotoxizität bedingt
durch den Quercetingehalt. Deutsche Apotheker Zeitung, 1988, 128:1364–1366.
120. Schimmer O et al. The mutagenic potencies of plant extracts containing quercetin
in Salmonella typhimurium TA 98 and TA 100. Mutation Research, 1988, 206:201–208.
121. Schimmer O et al. An evaluation of 55 commercial plant extracts in the Ames
mutagenicity test. Pharmazie, 1994, 49:448–451.
122. Leuschner J. Preclinical toxicological profile of Hypericum extract LI 160. Second
International Congress on Phytomedicine. Munich, 1996.
123. Siegers CP et al. Zur Frage der Phototoxizität von Hypericum. Nervenheilkunde, 1993,
124. Roots I et al. Evaluation of photosensitization of the skin upon single and multiple
dose intake of Hypericum extract. In: Second International Congress on Phytomedicine.
Munich, 1996.
125. Golsch S et al. Reversible Erhöhung der Photosensitivität im UV-B-Bereich durch
Johanniskrautextrakt-Präparate. Hautarzt, 1997, 48:249–252.
126. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St
John’s wort. Lancet, 1998, 352:1121.
127. Herberg KW. Psychotrope Phytopharmaka im Test. Alternative zu synthetischen
Psychopharmaka? Therapiewoche, 1994, 44:704–713.
128. Schmidt U et al. Johanniskraut-Extrakt zur ambulanten Therapie der Depression.
Aufmerksamkeit und Reaktionsvermögen bleiben erhalten. Fortschritt der Medizin,1993, 111:339–342.